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Abstract
Background: Given the increasing rate of overweight and the burden of metabolic syndrome (MetS) on
cardiovascular disease development, better understanding of the syndrome is of great importance. Therefore, the
objectives were to examine whether interleukin-6 (IL-6) and adiponectin are associated with MetS, and whether this
association is mediated by components of the MetS.
Methods: During 2011–2012, 284 individuals (159 men, 53 ± 9 years, 125 women 52 ± 9 years) without
cardiovascular disease, type 1 diabetes mellitus, high-grade inflammatory disease, living in the greater Athens area,
Greece, participated in clinical examination. Adiponectin and IL-6 were measured in fasting plasma samples. MetS
was defined according to the International Diabetes Federation (IDF) and the American Heart Association/National
Heart, Lung, and Blood Institute (AHA/NHLBI) criteria.
Results: MetS was present in 37 % (IDF) and 33 % (AHA/NHLBI) of the study population (P < 0.001).
Adiponectin was inversely associated with MetS (odds ratio, 95 % confidence interval: 0.829, 0.762- 0.902 for
MetS-IDF, and 0.840, 0.772- 0.914 for MetS-AHA/NHLBI). Body mass index (BMI), waist circumference, high
density lipoprotein (HDL)-cholesterol, triglyceride and insulin concentration mediated the association
between adiponectin and MetS-IDF (z-test, standard error, P-value: 2.898, 0.012, 0.004, for BMI; 2.732, 0.012,
0.006 for waist circumference; 2.388, 0.011, 0.017 for HDL-cholesterol; 2.163, 0.010, 0.031 for triglyceride; 2.
539, 0.010, 0.011 for insulin). Similarly, BMI, waist circumference, HDL-cholesterol and insulin concentration
mediated the association between adiponectin and MetS-AHA/NHLBI (z-test, standard error, P-value: 2.633, 0.
011, 0.008 for BMI; 2.441, 0.011, 0.015 for waist circumference; 1.980, 0.010, 0.048 for HDL-cholesterol; 2.225,
0.009, 0.026 for insulin). However, adiponectin remained significantly associated with MetS. IL-6 was not
significantly associated with MetS.
Conclusion: MetS components, in particular obesity and lipid indices, as well as serum insulin levels,
mediate the association between adiponectin and MetS as defined by both the IDF and AHA/NHLBI criteria.
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Background
Metabolic syndrome (MetS) is a cluster of factors of
clinical importance that increases the risk of cardiovas-
cular disease (CVD). These factors are widely accepted
indices of obesity, metabolic function and blood pressure
homeostasis [1]. Cardiovascular disease (CVD) incidence
has been recently associated with dyslipidemia, diabetes
mellitus and hypertension in a cohort study of CVD
epidemiology in Greece [2]. Several organizations for-
mulated simple criteria for the diagnosis of MetS in the
clinical practice in order to modify risk factors for CVD
development through lifestyle changes. The World
Health Organization, WHO, (1998) consultation group,
the European Group for Study of Insulin Resistance,
EGIR, (1999), and the American Association of Clinical
Endocrinologists, AACE, (2003) emphasized insulin re-
sistance as the underlying cause of MetS and required
evidence of insulin resistance for diagnosis. The National
Cholesterol Education Program Adult Treatment Panel
III, NCEP ATP III, (2001) aimed at identifying people at
higher long-term risk for atherosclerotic cardiovascular
disease who deserved lifestyle intervention to reduce
risk. The International Diabetes Federation, IDF, writing
group (2005) considered that abdominal obesity is
strongly correlated with insulin resistance, and made
the presence of abdominal obesity a prerequisite for
the diagnosis of MetS. The American Heart Association/
National Heart, Lung, and Blood Institute, AHA/NHLBI,
(2005) scientific statement revised the NCEP ATP III cri-
teria as regards the threshold for impaired fasting glucose.
Neither the NCEP ATP III nor the AHA/NHLBI criteria
drew conclusions on mechanistic pathogenesis [3].
The occurrence of MetS has been characterized as a
global epidemic. The two most widely used definitions
of MetS are based on the NCEP ATP III (2001) and the
IDF (2005) criteria [1]. The prevalence of MetS in the
Greek population was evaluated in two population-based
epidemiological studies, the ATTICA study [4] and the
MetS Greece Study [5]. The prevalence of MetS was
23.6 % [5], according to the NCEP ATP III definition,
and 48.9 % according to the IDF definition [6]. The most
prevalent abnormality among subjects with the MetS
was obesity, particularly abdominal obesity. Abdominal
obesity is considered the predominant underlying cause
of MetS and is associated with both insulin resistance and
low-grade chronic inflammation [3]. Waist circumference
is a widely used index of abdominal obesity, and was
found to be a better predictor of MetS compared with
BMI, waist-to-hip ratio and waist-to-height ratio [7].
Metabolic health has been associated with lower con-
centrations of pro-inflammatory cytokines (e.g. IL-6),
and higher concentrations of anti-inflammatory adipo-
kines (e.g. adiponectin) in both obese and non-obese
adults [8]. Presence of MetS and its components have
been associated with increased levels of IL-6 and de-
creased levels of adiponectin [3, 9]. A cross-sectional
data analysis from the Diet and Omega-3 Intervention
Trial on Atherosclerosis (DOIT) showed that serum
levels of IL-6 were significantly higher in subjects with
MetS compared to those without MetS, but there was
no significant association between IL-6 and increasing
MetS components [10]. On the contrary, the proportion
of subjects with MetS, declined across sex-specific
adiponectin quartiles in the context of the Carotid
Ultrasound Disease Assessment Study [11].
Given the increasing rates of overweight and obesity,
as well as the burden of MetS on cardiovascular disease
development, better understanding of the syndrome is of
great importance. Thus, the present study evaluated the
prevalence of MetS in a sample of the Greek population,
using two definitions which include an index of abdom-
inal obesity and differ only by the waist circumference
criteria. The hypothesis was that adiponectin and IL-6
plasma concentration is associated with MetS through
its components. Therefore, the aims of the present study
were to examine i) whether IL-6 or adiponectin concen-
tration is associated with MetS, and ii) whether this
association is mediated by components of the MetS. The
ability of IL-6 or adiponectin concentration in identify-
ing individuals with MetS was also evaluated.
Methods
Participants
This was a cross-sectional study carried out in the
greater area of Athens (78 % urban and 22 % rural re-
gions) during 2011–2012. The study population con-
sisted of individuals aged > 30 years from the general
population. Participants responded to an invitation to
health evaluation which was published at the partici-
pants’ workplace. Five hundred individuals participated
in the initial evaluation (Fig. 1). The sampling was based
on a feasibility basis, and the evaluation was performed
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at each participant’s workplace or home by trained
personnel (cardiologists, general practitioners, dieti-
tians and nurses).
Participants diagnosed with cardiovascular disease (i.e.
myocardial infarction, angina pectoris, other identified
forms of ischemia; coronary revascularization: coronary
artery bypass surgery and percutaneous coronary inter-
vention, heart failure of different types, chronic arrhyth-
mias, or stroke) were excluded from the study. Other
exclusion criteria were presence of high-grade chronic
inflammatory disease (e.g. rheumatoid arthritis, inflam-
matory bowel disease, atopic dermatitis, and asthma),
viral infections, cold or flu, acute respiratory infection,
dental problems, any type of surgery the month preced-
ing the study, and type 1 diabetes mellitus.
Two hundred eighty four participants who were eligible
to participate in the study and had complete lifestyle, clin-
ical and biochemical data were included in the present
study (Fig. 1); 159 participants were men (53 ± 9 years) and
125 were women (52 ± 9 years). No significant differences
were observed between participants who were finally in-
cluded in the study and the rest of the participants who
were excluded, as regards age and sex (P > 0.30, for all).
Lifestyle evaluation
Dietary habits were evaluated with a validated semi-
quantitative food-frequency questionnaire [12]; overall
dietary habits were evaluated using the MedDietScore
(range 0–55) that incorporates the inherent characteris-
tics of the Mediterranean diet [13]. Smokers were de-
fined as those who were smoking at least one cigarette
per day during the past year or had recently stopped
smoking (within the last 12 months); the rest of the par-
ticipants were defined as non-smokers. Passive smokers
were defined as those who were exposed to other peo-
ples’ smoke for more than 30 min/day and more than
5 days/week. The criteria for defining passive smoking
were based on literature addressing the biologic effects of
second-hand smoke on the cardiovascular system [14, 15].
Physical activity level was evaluated with the International
Physical Activity Questionnaire (IPAQ), modified and
adapted for the Greek population. Physical activity was
classified as vigorous, moderate and walking physical
activity and expressed in MET-minutes per week
(MET.min.wk−1). Total physical activity level and sit-
ting hours per day were also evaluated [16].
Clinical evaluation
Resting blood pressure was measured twice on the right
arm with an electronic monitor device. All participants
were at least 30 min at rest before measurement which
was performed in sitting position. Diagnosis and current
medication treatment for hypertension, hyperlipidemia
and type 2 diabetes mellitus were recorded in a self-
administered questionnaire. Waist circumference (in
centimeters, cm) was measured in the middle between
the 12th rib and the iliac crest. Hip circumference (in
cm) was measured around the buttocks at the level of
the maximum extension. Height was measured to the
nearest 0.5 cm, without shoes, back against the wall
tape, and eyes looking straight ahead. Weight was
measured with a lever balance, to the nearest 100 g,
without shoes, in light undergarments. BMI was cal-
culated as weight (in kilograms, kg) divided by height
(in meters squared, m2). Overweight was defined as
BMI between 25 and 29.9 kg/m2, while obesity as
BMI greater than 29.9 kg/m2, based on the WHO
criteria.
Blood collection and biochemical analyses
Venous blood samples were collected between 08:00 and
10:00, after 12 h overnight fast, with the participant in
sitting position. Instructions about the preparation before
blood collection were given to each participant either by
telephone or by e-mail. Fasting serum was obtained by
collecting blood into silicone coated Vacutainer Tubes
(Becton Dickinson) with clot activator. Blood was allowed
to clot at room temperature (18 – 25 °C) for 60 min and
Participants in the initial evaluation
(2011-2012)
n = 500
Participants excluded due to
not following eligibility criteria (n=121) 
not providing blood samples (n=65)
not having complete lifestyle or clinical data (n=30)
Participants included in the study
n= 284
Men (n= 159) 
median (25 , 75 ):
53 (47, 60) years old
Women (n= 125) 
median (25 , 75 ):
52 (45, 59) years old
Men (n=280)
median (25 , 75 ):
53 (47, 60) years old
Women (n= 220)
median (25 , 75 ):
52 (46, 61) years old
Fig. 1 Study flowchart
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immediately centrifuged for 10 min at 1,500xg before iso-
lation of the serum fraction. Fasting plasma was obtained
by collecting blood into K2-EDTA (EDTA-dipotassium
salt) Vacutainer Tubes (Becton Dickinson); the final
EDTA concentration in the samples was 4 mmol/L. The
EDTA blood samples were centrifuged within 60 min at
room temperature for 10 min at 1,500xg. Plasma and
serum aliquots were stored at −80 °C until use.
Serum total cholesterol, HDL-cholesterol, triglyceride,
and glucose concentration were measured on a COBAS
8000/ ROCHE analyzer, based on colorimetric detection.
The CHOD-PAP method was applied for total cholesterol
(2.06 % intra-assay coefficient of variation-CV, 0.94 %
inter-assay CV) and HDL cholesterol (1.50 % intra-CV,
0.80 % inter-CV), the GPO-PAP method for triglycerides
(1.80 % intra-CV, 1.98 % inter-CV), and the GOD-PAP
method for glucose (1.97 % intra-CV, 1.28 % inter-CV).
All measurements were carried out at the same laboratory
(BIOMED S.A., accreditation standard ELOT EN ISO
15189, Hellenic Accreditation System – E.SY.D.). None of
the study participants had triglyceride values >4.5 mmol/
L. LDL-cholesterol was estimated with the Friedewald
equation: (total cholesterol) – (HDL cholesterol) – (triglyc-
erides/2.2) [17]. All biochemical indices were measured in
duplicate and are expressed in mmol/L.
Serum insulin concentration was measured on a
TOSOH AIA-600 II automated enzyme immunoassay
analyzer using a two-site immune-enzymometric assay.
The intra- and inter-assay CVs were <3 %. Insulin con-
centration is expressed in mU/L. IL-6 and adiponectin
concentrations were measured in plasma EDTA samples.
IL-6 was measured by a commercially available ELISA
method (Quantikine HS, R&D Systems Europe Ltd.,
Abingdon, U.K.) with an assay range of 0.156 -10 pg/ml.
Adiponectin was measured by a commercially available
ELISA method (Quantikine, R&D Systems Europe Ltd.,
Abingdon, U.K.) with an assay range of 3.9 - 250 ng/ml.
The intra- and inter-assay CVs were <10 % for IL-6 and
<7 % for adiponectin. Il-6 and adiponectin concentra-
tions are expressed in pg/ml and μg/ml, respectively.
Definition of metabolic syndrome
Metabolic syndrome was defined by the AHA/NHLBI
and the IDF criteria [3]. According to the AHA/NHLBI
definition, the diagnosis of MetS is established when
3 of 5 factors are present: abdominal obesity, elevated
triglycerides, reduced HDL cholesterol, elevated blood
pressure, elevated fasting glucose or type 2 diabetes
mellitus. The diagnostic criteria are: waist circumference
≥102 cm for men and ≥88 cm for women, triglycerides
≥1.7 mmol/L, HDL-cholesterol <1.03 mmol/L for men
and <1.3 mmol/L for women, systolic blood pressure
(SBP) ≥130 mmHg or diastolic blood pressure (DBP)
≥85 mmHg, and fasting blood glucose ≥5.6 mmol/L.
Participants on drug treatment for elevated triglycerides,
reduced HDL-cholesterol, elevated blood pressure or
hyperglycemia were considered as meeting the aforemen-
tioned criteria, respectively. Presence of MetS was also de-
fined by the IDF criteria. According to the IDF, one must
have abdominal obesity (waist circumference ≥94 cm for
men, and ≥80 cm for women of Europid origin) or BMI
≥30 kg/m2 and any two of the other risk factors men-
tioned in the AHA/NHLBI definition.
Bioethics
The study adhered to the Declaration of Helsinki princi-
ples, and it was approved by the Bioethics Committee of
Harokopio University, Athens. Participants were in-
formed about the aims and the procedure of the study
and they provided their written consent prior to the col-
lection of any information.
Statistical analysis
The prevalence of MetS was determined as frequen-
cies, using both definitions. Continuous variables are
expressed as median and interquartile range (IQR).
Categorical variables are expressed as frequencies.
Normal distribution of continuous variables was tested
with the Kolmogorov-Smirnov test and P-P plots.
Adiponectin and IL-6 had a rightly skewed distribu-
tion and the values were log-transformed (log10). The
association of continuous variables (i.e. age, HDL-
cholesterol, LDL-cholesterol, triglycerides, glucose, in-
sulin, SBP, DBP, BMI, waist circumference, IL-6 and
adiponectin) with MetS was evaluated using the non-
parametric Kolmogorov - Smirnov Z-test (due to the
skewed distribution of the variables), whereas the
Pearson Chi-Square test was used for the categorical
variables (i.e. sex and medical treatment for hyperten-
sion, hypercholesterolemia, type 2 diabetes mellitus).
Pearson’s unadjusted and partial (adjusted for sex and
age) correlation coefficient (r) was applied to evaluate
correlations between adiponectin, IL-6 and MetS compo-
nents (i.e. waist circumference, BMI, HDL-cholesterol,
triglycerides, glucose, insulin, SBP and DBP). Linear re-
gression was applied, where adiponectin or IL-6 was the
dependent variable and sex, age and MetS components
were the independent variables; results are presented as
beta coefficients and SE. The collinearity statistics (toler-
ance and variance inflation factor, VIF) showed that there
was no problem with multicollinearity. Logistic regression
was applied, where MetS was the dependent variable and
adiponectin or IL-6 was the independent variable, and ad-
justed for sex and age, and further adjusted for BMI, waist
circumference, HDL-cholesterol, triglyceride and insulin
concentration in order to test for the potential mediating
effect of these factors as regards the adiponectin - MetS
and IL-6-MetS association. Results are expressed as odds
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ratio (OR) and the corresponding 95 % confidence interval
(CI). The Sobel Test was used to determine whether the
indirect association between the independent variable (i.e.,
IL-6 or adiponectin) and the dependent variable (i.e.,
MetS) via the mediator is significantly different from zero
[18]. The test was performed online http://quantpsy.org/
sobel/sobel.htm. The receiver operating characteristic
(ROC) analysis was used to assess the ability of adiponec-
tin to discriminate between participants with MetS and
participants without MetS after adjustment for sex, age,
and further adjustment for BMI, waist circumference and
insulin concentration. Results are expressed as the area
under the ROC curve (AUC) and the corresponding 95 %
CI. The AUC provides a scale from 0.5 to 1.0 (i.e. 0.5 rep-
resents random chance and 1.0 indicates perfect discrim-
ination) by which to appraise the accuracy of adiponectin.
ROC analysis was performed using R (version 3.2.4
for Windows), package “pROC” [19]. SPSS version
21 (Statistical Package for Social Sciences, SPSS
Inc., Chicago, IL, USA) was used for all other stat-
istical analyses. All reported P-values are based on
two-sided tests, and statistical significance was set
at P < 0.05.
Results
Prevalence of MetS and comparison for lifestyle, clinical
and biochemical factors
Table 1 shows the general characteristics of the study
population, and the comparison between participants
with MetS and participants without MetS. The preva-
lence of MetS was 37 % of the total study population (32
women and 74 men) according to the IDF criteria, and
33 % (29 women and 66 men) according to the AHA/
NHLBI criteria. The prevalence of MetS differed signifi-
cantly between the two definitions (P < 0.001). Partici-
pants with MetS did not differ significantly as regards
current smoking habits (smokers vs. non-smokers, ciga-
rettes per day and years of smoking), passive smoking
(passive smokers vs. non-passive smokers), physical ac-
tivity level (MET.min.wk−1), sitting hours (h/day) or
dietary habits (portions of food group consumption per
wk and MedDietScore) compared with participants with-
out MetS as defined by either the IDF or the AHA/
NHLBI criteria (data not shown).
According to the unadjusted bivariate associations, adi-
ponectin was positively correlated with HDL-cholesterol
(r = 0.385, P < 0.001) and negatively correlated with
triglycerides (r = −0.362, P < 0.001), glucose (r = −0.219,
P < 0.001), insulin (r = −0.312, P < 0.001), SBP (r = −0.123,
P < 0.05), DBP (r = −0.128, P < 0.05), BMI (r = −0.171,
P < 0.01) and waist circumference (r = −0.391, P < 0.001).
On the contrary, IL-6 was negatively correlated with
HDL-cholesterol (r = −0.308, P < 0.001) and positively
correlated with triglycerides (r = 0.219, P < 0.001), insulin
(r = 0.125, P < 0.05), SBP (r = 0.124, P < 0.05), BMI (r =
0.267, P < 0.001) and waist circumference (r = 0.298, P <
0.001). Age was significantly correlated with triglyceride,
glucose and insulin concentration (r = 0.164, P < 0.01,
r = 0.265, P < 0.001, and r = 0.132, P < 0.05 respectively)
in the total study population. Age was also significantly
correlated with SBP and waist circumference (r = 0.346,
P < 0.001 and r = 0.132, P <0.05, respectively). Men had
significantly higher triglyceride, glucose and insulin
concentration, SBP and DBP, BMI and waist circumfer-
ence than women. On the contrary, men had lower
HDL-cholesterol than women (P < 0.001, for all). After
adjustment for age and sex, the association between
adiponectin and HDL-cholesterol (r = 0.282), triglycer-
ides (r = −0.319), glucose (r = −0.140), insulin (r = −0.305),
BMI (r = −0.161) and waist circumference (r = −0.208)
remained statistically significant. The association be-
tween IL-6 and HDL-cholesterol (r = −0.335), triglyc-
erides (r = 0.199), insulin (r = 0.130), BMI (r = 0.264)
and waist circumference (r = 0.333) remained statistically
significant after adjustment for sex and age. There was no
significant association between adiponectin and IL-6 ei-
ther in the unadjusted or the adjusted model.
In the multivariate adjusted models, adiponectin was
significantly associated with serum triglyceride concen-
tration (Table 2; Model 1 and Model 2) and waist
circumference (Table 2; Model 2). Insulin was an inde-
pendent associate of adiponectin (Table 2; Model 3, β =
−0.164, P = 0.006, and Model 4, β = −0.148, P = 0.011)
after adjusting for sex, age and MetS components. Waist
circumference did not remain an independent associate
of adiponectin after adjustment for insulin (Table 2;
Model 4). IL-6 was significantly associated with HDL-
cholesterol, BMI and waist circumference in the
multivariate adjusted models (Table 3). Insulin was
not an independent associate of IL-6 after adjustment
for sex, age and MetS components (Table 3; Model 3
and Model 4).
Assessing the potential mediation effect of insulin, BMI,
waist circumference, HDL-cholesterol and triglycerides
Plasma adiponectin concentration was significantly asso-
ciated with MetS (OR, 95 % CI: 0.829, 0.762- 0.902 for
MetS-IDF, and 0.840, 0.772- 0.914 for MetS-AHA/
NHLBI) (Table 4), whereas plasma IL-6 concentration
was not significantly associated with MetS (Table 5).
Adiponectin remained significantly associated with MetS
after controlling for insulin, BMI, waist circumference,
HDL-cholesterol or triglyceride concentration. However,
adiponectin was not significantly associated with MetS-
AHA/NHLBI after controlling for triglyceride concen-
tration (Table 4). Results of the Sobel Test showed that
the indirect association between adiponectin and
MetS-IDF was significantly different from zero after
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Table 2 Multivariate adjusted associations between metabolic syndrome components and log10(adiponectin)
Model 1 R2 = 0.376 Model 3 R2 = 0.393
B SE β t P B SE β t P
Sex (women/men) −0.194 0.025 −0.405 −7.618 <0.001 −0.189 0.025 −0.395 −7.456 <0.001
Age (years) 0.005 0.001 0.210 4.061 <0.001 0.005 0.001 0.202 3.942 <0.001
HDL-cholesterol (mmol/L) 0.002 0.001 0.119 1.931 0.055 0.002 0.001 0.119 1.948 0.053
Triglycerides (mmol/L) −0.001 0.000 −0.213 −3.538 <0.001 −0.001 0.000 −0.169 −2.736 0.007
Glucose (mmol/L) −0.001 0.001 −0.046 −0.842 0.401 −0.001 0.001 −0.040 −0.741 0.459
Body mass index (kg/m2) −0.004 0.003 −0.074 −1.432 0.153 0.000 0.003 −0.004 −0.074 0.941
Insulin (mU/L) - - - - - −0.007 0.002 −0.164 −2.755 0.006
Model 2 R2 = 0.380 Model 4 R2 = 0.394
B SE β t P B SE β t P
Sex (women/men) −0.172 0.028 −0.359 −6.206 <0.001 −0.179 0.028 −0.375 −6.410 <0.001
Age (years) 0.006 0.001 0.211 4.103 <0.001 0.005 0.001 0.205 3.999 <0.001
HDL-cholesterol (mmol/L) 0.002 0.001 0.119 1.954 0.052 0.002 0.001 0.117 1.912 0.057
Triglycerides (mmol/L) −0.001 0.000 −0.201 −3.313 0.001 −0.001 0.000 −0.165 −2.670 0.008
Glucose (mmol/L) −0.001 0.001 −0.043 −0.784 0.434 −0.001 0.001 −0.037 −0.674 0.501
Waist circumference (cm) −0.002 0.001 −0.117 −1.975 0.049 −0.001 0.001 −0.054 −0.848 0.398
Insulin (mU/L) - - - - - −0.006 0.002 −0.148 −2.558 0.011
Table 1 Clinical and biochemical factors in the total study sample, participants without metabolic syndrome and participants with
metabolic syndrome
IDF (n, %) AHA/NHLBI (n, %)
All no MetS (178, 63) MetS (106, 37) no MetS (189, 67) MetS (95, 33)
Age (years) 52.00 (46.00, 59.88) 51.00 (45.00, 56.00) 56.50 (49.00, 62.25)b 51.00 (45.00, 56.50) 56.00 (49.00, 62.00)b
Sex (men, women), n (%) 159 (56)/ 125(44) 85 (48)/ 93 (52) 74 (70)/ 32 (30)a 93 (49)/ 96 (51) 66 (69)/ 29 (31)a
HDL-cholesterol (mmol/L) 1.29 (1.08, 1.51) 1.38 (1.21, 1.58) 1.09 (0.94, 1.29)b 1.38 (1.20, 1.58) 1.08 (0.94, 1.25)b
LDL-cholesterol (mmol/L) 3.43 (2.91, 4.04) 3.46 (2.97, 4.06) 3.30 (2.73, 3.92) 3.45 (2.94, 3.95) 3.38 (2.90, 4.10)
Triglycerides (mmol/L) 1.15 (0.86, 1.62) 1.05 (0.76, 1.30) 1.61 (1.14, 2.18)b 1.05 (0.77, 1.30) 1.70 (1.13, 2.33)b
Glucose (mmol/L) 4.99 (4.72, 5.35) 4.90 (4.69, 5.17) 5.22 (4.86, 5.71)b 4.90 (4.68, 5.17) 5.24 (4.90, 5.82)b




213 (75)/ 49 (17.3) 152 (85.4)/ 14 (7.9) 61 (57.5)/ 35 (33)a 155 (82)/ 20 (10.6) 58 (61.1)/ 29 (30.5)a
Hypercholesterolemia
(no/yes), n (%)
161 (56.7)/ 109 (38.4) 118 (66.3)/ 52 (29.2) 43 (40.6)/ 57 (53.8)a 122 (64.6)/ 57 (30.2) 39 (41.1)/ 52 (54.7)a
Type 2 diabetes mellitus
(no/yes), n (%)
250 (88)/ 14 (4.9) 165 (92.7)/ 2 (1.1) 85 (80.2)/ 12 (11.3)a 175 (92.6)/ 2 (1.1) 75 (78.9)/ 12 (12.6)a
SBP (mmHg) 123.00 (114.00, 133.50) 118.00 (109.75, 127.00) 133.00 (124.75, 138.00)b 118.50 (110.00, 128.00) 133.00 (125.25, 138.00)b
DBP (mmHg) 79.00 (70.00, 86.00) 75.25 (69.00, 82.40) 84.00 (77.00, 90.00)b 76.00 (69.00, 83.00) 85.00 (77.00, 90.00)b
BMI (kg/m2) 27.25 (24.73, 31.00) 25.40 (23.90, 29.00) 29.80 (27.20, 32.40)b 25.70 (23.95, 28.85) 30.00 (28.00, 32.70)b
Waist circumference (cm) 96.00 (86.00, 106.00) 90.00 (81.25, 98.88) 103.00 (97.75, 111.25)b 90.00 (82.00, 99.00) 105.00 (98.00, 112.00)b
IL-6 plasma concentration
(pg/mL)
1.621 (0.983, 2.696) 1.392 (0.897, 2.209) 2.152 (1.274, 3.026)b 1.394 (0.897, 2.329) 2.099 (1.391, 3.036)b
Adiponectin plasma
concentration (μg/mL)
7.419 (4.763, 10.516) 8.471 (5.883, 12.944) 5.546 (3.799, 8.693)b 8.473 (5.680, 12.579) 5.476 (4.072, 8.454)b
Quantitative variables are expressed as median (25th, 75th IQR)
aPearson Chi-Square, P ≤ 0.001 for comparison between no MetS and MetS separately for two definitions of MetS
bKolmogorov-Smirnov Z Test, P ≤ 0.001 for comparison between no MetS and MetS separately for two definitions of MetS
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controlling for insulin (z-test = 2.539, SE = 0.010, P =
0.011), BMI (z-test = 2.898, SE = 0.012, P = 0.004), waist
circumference (z-test = 2.732, SE = 0.012, P = 0.006), HDL-
cholesterol (z-test = 2.388, SE = 0.011, P = 0.017) or trigly-
ceride concentration (z-test = 2.163, SE = 0.010, P = 0.031).
Similarly, the indirect association between adiponec-
tin and MetS-AHA/NHLBI was significantly different
from zero after controlling for insulin (z-test = 2.225,
SE = 0.009, P = 0.026), BMI (z-test = 2.633, SE = 0.011,
P = 0.008), waist circumference (z-test = 2.441, SE = 0.011,
P = 0.015) or HDL-cholesterol (z-test = 1.980, SE = 0.010,
P = 0.048).
Accuracy of factors associated with the identification
of MetS
The AUC and the 95 % CI were calculated for adipo-
nectin after adjustment for sex, age, and further ad-
justment for insulin, BMI or waist circumference, in
order to assess the ability of adiponectin to discrimin-
ate between participants with MetS and participants
without MetS. Adiponectin performed better than
chance (i.e., the AUC was significantly greater than
0.5) in classifying correctly subjects with MetS, both
in the model that adjusted only for sex and age, as
well as in the model that further adjusted for insulin,
BMI or waist circumference (Table 6). The results
were similar independently of the definition used.
Since IL-6 concentration was not significantly associ-
ated with MetS, the AUC was not calculated for this
biomarker.
Discussion
The major findings of the present study are summarized
as follows. Adiponectin was significantly associated with
prevalent MetS, whereas IL-6 was not significantly asso-
ciated with MetS. MetS components mediated the asso-
ciation between adiponectin and MetS, but adiponectin
remained significantly associated with MetS. Adiponec-
tin had a high discriminative accuracy for MetS inde-
pendently of the definition used. All the results were
similar regardless of the definition used. Even though ab-
dominal obesity is a prerequisite for the IDF definition
and the cut-off value of waist circumference is different
between the two definitions used in the present study,
the results indicated that the IDF and AHA/NHLBI
definitions for evaluating presence of MetS are prac-
tically identical. However, we could not draw definite
conclusions based on the results of the present study
due to two main limitations, i.e. the cross-sectional
design of the study and the relatively small sample
size. Nevertheless, the importance of the present
study lies in exploring MetS beyond its clinical and
biochemical constituents.
Obesity, particularly abdominal obesity, has been iden-
tified as a significant constituent of MetS. According to
the IDF definition, abdominal obesity, as assessed by
waist circumference, is an essential diagnostic criterion
because of the strength of the evidence linking waist cir-
cumference with metabolic abnormalities [20]. Dyslipi-
daemia was the major metabolic abnormality and the
second most frequent MetS component after abdominal
Table 3 Multivariate adjusted associations between metabolic syndrome components and log10(IL-6)
Model 1 R2 = 0.199 Model 3 R2 = 0.220
B SE β t P B SE β t P
Sex (women/men) −0.079 0.040 −0.117 −1.951 0.052 −0.090 0.040 −0.134 −2.224 0.027
Age (years) 0.008 0.002 0.211 3.605 <0.001 0.008 0.002 0.216 3.720 <0.001
HDL-cholesterol (mmol/L) −0.008 0.002 −0.265 −3.817 <0.001 −0.008 0.002 −0.286 −4.110 <0.001
Triglycerides (mmol/L) 0.000 0.000 0.067 0.985 0.326 0.000 0.000 0.039 0.564 0.573
Glucose (mmol/L) −0.002 0.002 −0.050 −0.803 0.422 −0.002 0.002 −0.059 −0.953 0.342
Body mass index (kg/m2) 0.013 0.004 0.201 3.483 0.001 0.011 0.004 0.172 2.793 0.006
Insulin (mU/L) - - - - - 0.005 0.004 0.084 1.296 0.196
Model 2 R2 = 0.236 Model 4 R2 = 0.253
B SE β t P B SE β t P
Sex (women/men) −0.171 0.043 −0.256 −3.991 <0.001 −0.179 0.043 −0.268 −4.123 <0.001
Age (years) 0.007 0.002 0.205 3.586 <0.001 0.008 0.002 0.214 3.740 <0.001
HDL-cholesterol (mmol/L) −0.007 0.002 −0.261 −3.884 <0.001 −0.008 0.002 −0.287 −4.242 <0.001
Triglycerides (mmol/L) 0.000 0.000 0.040 0.591 0.555 0.000 0.000 0.027 0.397 0.692
Glucose (mmol/L) −0.002 0.002 −0.067 −1.110 0.268 −0.002 0.002 −0.072 −1.184 0.238
Waist circumference (cm) 0.008 0.002 0.320 4.872 <0.001 0.008 0.002 0.312 4.396 <0.001
Insulin (mU/L) - - - - - 0.001 0.004 0.025 0.382 0.703
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Table 4 Association between plasma adiponectin concentration and metabolic syndrome, and the mediation effect of MS components
OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI)
MetS-IDF Age (years) 1.087 (1.052- 1.123) 1.084 (1.048- 1.122) 1.088 (1.051- 1.126) 1.084 (1.045- 1.124) 1.089 (1.051- 1.128) 1.075 (1.037- 1.113)
Sex (men) 0.757 (0.404- 1.418) 0.685 (0.353-1.330) 0.652 (0.330- 1.290) 1.656 (0.784- 3.497) 0.976 (0.487- 1.956) 0.743 (0.372- 1.486)
Adiponectin (μg/ml) 0.829 (0.762- 0.902) 0.870 (0.797-0.949) 0.837 (0.764- 0.916) 0.846 (0.769- 0.930) 0.875 (0.798- 0.958) 0.894 (0.818- 0.977)
Insulin (mU/L) - 1.131 (1.069-1.197) - - - -
BMI (kg/m2) - - 1.193 (1.113- 1.278) - - -
Waist circumference (cm) - - 1.098 (1.064- 1.133) - -
HDL-cholesterol (mmol/L) - - - 0.904 (0.873- 0.937) -
Triglycerides (mmol/L) - - - - 1.020 (1.013- 1.027)
MetS-AHA/NHLBI Age (years) 1.082 (1.047- 1.117) 1.080 (1.043-1.118) 1.083 (1.046- 1.122) 1.078 (1.039- 1.117) 1.086 (1.047- 1.126) 1.070 (1.031- 1.110)
Sex (men) 0.803 (0.425- 1.517) 0.720 (0.366-1.418) 0.667 (0.331- 1.343) 1.811 (0.844- 3.886) 1.103 (0.534- 2.276) 0.779 (0.377- 1.609)
Adiponectin (μg/ml) 0.840 (0.772- 0.914) 0.887 (0.813-0.969) 0.850 (0.776- 0.931) 0.861 (0.783- 0.947) 0.897 (0.817- 0.985) 0.921 (0.842- 1.007)
Insulin (mU/L) - 1.147 (1.083-1.215) - - - -
BMI (kg/m2) - - 1.212 (1.129- 1.302) - - -
Waist circumference (cm) - - 1.105 (1.070- 1.141) - -
HDL-cholesterol (mmol/L) - - - 0.884 (0.850- 0.919) -















Table 5 Association between plasma IL-6 concentration and metabolic syndrome, and the mediation effect of MS components
OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI)
MetS-IDF Age (years) 1.072 (1.040- 1.105) 1.072 (1.038-1.108) 1.076 (1.042- 1.111) 1.072 (1.037- 1.109) 1.091 (1.053- 1.129) 1.068 (1.032- 1.105)
Sex (men) 0.357 (0.205- 0.624) 0.405 (0.223-0.738) 0.345 (0.190- 0.626) 0.957 (0.481- 1.907) 0.690 (0.364- 1.309) 0.493 (0.262- 0.927)
IL-6 (pg/ml) 1.086 (0.975- 1.210) 1.051 (0.935-1.182) 1.054 (0.934- 1.191) 1.021 (0.894- 1.166) 0.968 (0.853- 1.099) 1.033 (0.907- 1.176)
Insulin (mU/L) - 1.154 (1.090-1.221) - - - -
BMI (kg/m2) - - 1.139 (1.073- 1.209) - - -
Waist circumference (cm) - - - 1.097 (1.065- 1.131) - -
HDL-cholesterol (mmol/L) - - - - 0.893 (0.861- 0.925) -
Triglycerides (mmol/L) - - - - - 1.023 (1.015- 1.030)
MetS-AHA/NHLBI Age (years) 1.066 (1.034- 1.098) 1.067 (1.033-1.103) 1.072 (1.038- 1.108) 1.068 (1.031- 1.105) 1.090 (1.051- 1.131) 1.063 (1.026- 1.102)
Sex (men) 0.395 (0.224- 0.695) 0.456 (0.246-0.844) 0.372 (0.201- 0.689) 1.171 (0.573- 2.395) 0.923 (0.467- 1.824) 0.579 (0.299- 1.123)
IL-6 (pg/ml) 1.064 (0.954- 1.186) 1.024 (0.907-1.156) 1.019 (0.894- 1.162) 0.983 (0.854- 1.131) 0.918 (0.805- 1.048) 0.995 (0.870- 1.139)
Insulin (mU/L) - 1.168 (1.103-1.237) - - - -
BMI (kg/m2) - - 1.167 (1.094- 1.244) - - -
Waist circumference (cm) - - - 1.110 (1.075- 1.146) - -
HDL-cholesterol (mmol/L) - - - - 0.865 (0.830- 0.902) -















obesity, found in our sample. Dyslipidaemia, which is
primarily characterized by elevated plasma FFA and tri-
glycerides, decreased levels of HDL-cholesterol, and ab-
normal LDL composition, is a main risk factor for CVD
incidence and mortality. Normalization of fasting blood
lipid levels can improve the cardiovascular risk profile of
individuals. The Mediterranean dietary pattern is a life-
style factor which consists of food groups that are
already known to ameliorate dyslipidaemia and decrease
the incidence of cardiovascular events, probably by
means of their nutrient content, such as resveratrol and
polyphenols in red wine, fish oil and proteins, poly-
phenols, and phytosterols in fruits and vegetables
[21]. In the present study, participants with MetS did
not differ significantly as regards food group con-
sumption or their overall score of adherence to the
Mediterranean dietary pattern compared with participants
without MetS. However, this was a cross-sectional study,
and the participants’ dietary habits were evaluated once
using a semi-quantitative food-frequency questionnaire,
therefore evaluation of true intake may be inaccurate due
to daily and seasonal effects, as well as other personal
characteristics [12].
Metabolic health has been associated with an altered
secretion pattern of adipokines. Specifically, production
of pro-inflammatory cytokines is enhanced, whereas pro-
duction of adiponectin is inhibited in the adipose tissue
in the presence of obesity [22]. Furthermore, certain adi-
pokines, such as leptin, are mainly associated with total
obesity, whereas others, such as IL-6 and adiponectin
may be more closely linked with abdominal obesity [23].
It is estimated that 15–35 % of total IL-6 concentration
in the circulation originates from the adipose tissue
where it is produced by non-adipocytes, such as fibro-
plasts, endothelial cells, and monocytes [24]. Adiponec-
tin is abundantly expressed in the white adipose tissue
by mature adipocytes [25, 26], and it circulates in differ-
ent oligomeric forms, i.e. low-molecular weight (LMW)
trimers, medium-molecular weight (MMW) hexamers,
and high-molecular weight (HMW) oligomers [27].
HMW adiponectin has been suggested as the biologic-
ally active form of adiponectin [28], and circulating
HMW adiponectin, rather than total adiponectin, has
been associated with insulin sensitivity [29], as well as
with anteroposterior diameter of infra-renal abdominal
aorta (APAO), an ultrasound early marker of athero-
sclerosis [30]. Nevertheless, there has been found a
strong association between total and HMW adiponectin
in circulation [31, 32]. In addition, both total and HMW
adiponectin blood levels have been inversely associated
with biomarkers of inflammation, endothelial dysfunc-
tion, and insulin resistance [33], as well as with prevalent
or incident MetS [34, 35].
There has been evidence for a reciprocal association
between adiponectin, pro-inflammatory cytokines (e.g.
IL-6 and TNF-a), and the acute-phase reactant CRP,
each regulating the expression of the others in a feed-
back loop [36]. IL-6 is a central mediator of the
Table 6 Discriminative accuracy of adiponectin, insulin, BMI and waist circumference in the prediction of prevalent metabolic syndrome
AUC 95 % CI
MetS-IDF Adiponectin 0.744 0.685–0.801
Insulin 0.783 0.730–0.837
BMI 0.752 0.688–0.815
Waist circumference 0.798 0.743–0.853
Adiponectin and insulin 0.813 0.760–0.858
Adiponectin and BMI 0.793 0.734–0.850
Adiponectin and waist circumference 0.825 0.767–0.883
Adiponectin and insulin and BMI 0.829 0.780–0.874
Adiponectin and insulin and waist circumference 0.858 0.814–0.896
MetS-AHA/NHLBI Adiponectin 0.731 0.672–0.791
Insulin 0.789 0.734–0.843
BMI 0.758 0.696–0.817
Waist circumference 0.803 0.746–0.859
Adiponectin and insulin 0.818 0.763–0.862
Adiponectin and BMI 0.791 0.732–0.849
Adiponectin and waist circumference 0.822 0.767–0.879
Adiponectin and insulin and BMI 0.840 0.793–0.884
Adiponectin and insulin and waist circumference 0.860 0.813–0.899
All models were adjusted for sex and age
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acute-phase response because it can induce the pro-
duction of CRP from the liver [37] and the content
of adipose tissue in IL-6 is significantly associated
with the concentration of IL-6 and CRP in the circu-
lation [38]. Adiponectin, as an anti-inflammatory adi-
pokine, can inhibit IL-6 production [39], suppress
TNF-a levels [40], and reduce IL-6-stimulated CRP
secretion [41]. On the other hand, adiponectin gene
expression and secretion have been found to be
downregulated by IL-6, TNF-a [28], and CRP [42].
Based on the literature discussed so far, we measured
total adiponectin and IL-6 as representative inflamma-
tory indices in order to study the association with
metabolic indices and the prevalence of MetS.
In the present study, adiponectin was significantly and
inversely associated with waist circumference, whereas
IL-6 was significantly and positively associated with BMI
and waist circumference in the multivariate linear re-
gression models. These results are in accordance with
previous studies which have shown that adiponectin is
inversely associated with markers of adiposity such as fat
mass, BMI, waist circumference and waist-to-hip ratio in
multivariate linear regression models [43–46]. Central
obesity has been recognized as significant predictor of
high IL-6 levels in the circulation even after adjustment
for markers of lipid and glucose metabolism, blood pres-
sure, smoking status, sex and age [47]. Abdominal obes-
ity, assessed as waist circumference, has been found to
explain most of the variance in IL-6 levels after adjust-
ment for age, sex, smoking habits, alcohol consumption,
and physical activity level [48]. In the present study, adi-
ponectin was significantly and negatively associated with
serum triglycerides in the multivariate adjusted model,
and this association was attenuated, but remained sig-
nificant after adjustment for serum insulin concentra-
tion. IL-6 was significantly and negatively associated
with serum HDL-cholesterol in the multivariate adjusted
model, but this association was not affected after further
adjustment for serum insulin concentration. Previous
studies have shown that adipokines are associated with
insulin signalling and actions, and can therefore affect
lipid metabolism. Specifically, adiponectin can have
beneficial effects on lipid metabolism because of its
insulin-sensitizing effects, whereas IL-6 has been in-
volved in the dysregulation of insulin signalling and has
been associated with dyslipidaemia [49–52]. Since this
was a cross-sectional study, measurement of blood lipid,
insulin and adipokine levels are based on a single sam-
ple, and therefore we cannot draw conclusions regarding
cause-effect.
In the present study, adiponectin levels were inversely
associated with prevalent MetS even after adjustment for
MetS components using either definition. Similarly, pre-
vious studies have found that the odds ratio for either
prevalent or incident MetS is lower for the top quartile
of adiponectin compared with the bottom quartile even
after adjustments for age, sex, MetS components and
other MetS-related factors [11, 53–56]. In the present
study, IL-6 levels were not associated with MetS. Previ-
ous study has found that IL-6 is associated with MetS,
and that the top tertile of IL-6 is associated with in-
creased odds ratio for MetS compared with the bottom
tertile after adjustment for age and sex. Nevertheless,
further adjustment for BMI and insulin has attenuated
that association [57]. Similarly, IL-6 levels have not been
associated with MetS after adjustment for age, sex and
MetS components [58]. In the present study, adjustments
for MetS components (i.e. BMI, waist circumference,
HDL-cholesterol, triglyceride and insulin concentration)
were made in order to test the potential mediating effect
of these factors as regards the adiponectin-MetS associ-
ation. Furthermore, the indirect association between adi-
ponectin and MetS via the MetS components was
determined in order to provide for an explanation regard-
ing the association observed between adiponectin and
MetS. As far as we are aware of, this is the first study
which examines the mediation effect of MetS components
in the association between adiponectin and MetS found in
previous studies and in the present study as well.
In the present study, adiponectin had a high discrimina-
tive accuracy for MetS after adjustment for sex, age, and
after further adjustment for BMI, waist circumference and
insulin concentration, regardless of the definition used.
Previous studies have also found that adiponectin has a
high discriminative accuracy for MetS. In particular,
plasma adiponectin quartiles have been found to classify
correctly subjects with prevalent MetS after adjustment
for sex, age, BMI, and MetS-related factors [11]. Similarly,
plasma adiponectin has been found to have high discrim-
inative accuracy for prevalent MetS, and it has been ob-
served to be similar to the discriminative accuracy of BMI
in age and sex adjusted models [53]. Finally, a previous
study has found that adiponectin levels have a high dis-
criminative accuracy for incident MetS [56]. As far as we
are aware of, this is the first study that used two defini-
tions in order to diagnose presence of MetS, and that
evaluated the discriminative accuracy of adiponectin
in classifying correctly subjects with MetS by both
definitions.
Limitations of the present study have to be taken into
account. Firstly, this was a cross-sectional study which
does not allow for conclusions regarding causality. Sec-
ondly, this study included middle-aged white individuals,
without prevalent cardiovascular disease. Caution is thus
needed in the extrapolation of the findings to other
populations, i.e. younger, of other ethnicity or with car-
diovascular disease. Moreover, type 2 diabetes mellitus
and impaired fasting glucose were less prevalent than
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dyslipidemia or hypertension in the study population.
Therefore, we cannot exclude blood glucose as a signifi-
cant mediator between adiponectin and MetS. Finally,
the adipokines measured are only a small fraction of the
wide array of pro- and anti-inflammatory biochemical
indices that are produced by the adipose tissue.
This study has also strengths. Firstly, the measurement
of biochemical indices was performed by a single certi-
fied laboratory. Secondly, the prevalence of MetS was
evaluated by two definitions which are closely related
and differ only by the abdominal obesity criterion. This
allows for safer comparison between two existing defini-
tions of MetS, and tests for the role of abdominal obesity
in MetS. Furthermore, the adipokines measured were
selected because of their proved and consistent associ-
ation with adiposity, metabolism and inflammation. In
addition, adiponectin and IL-6 were chosen to be mea-
sured because of their opposite functions and effects in
metabolism and inflammation. Finally, this is one of the
few studies which provide for a plausible explanation for
the association between adiponectin and MetS.
Conclusions
Adiponectin was identified as a significant and consist-
ent parameter associated with MetS, whereas IL-6 was
suggested to be only a biomarker of the MetS state.
Moreover, MetS components which are indices of obes-
ity and lipid metabolism (i.e. waist circumference, BMI,
HDL-cholesterol and triglycerides), as well as insulin
levels mediate, but do not abolish the association be-
tween adiponectin and MetS.
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